Studies in China have shown that the HAA regimen can increase the rate of early remission in induction therapy among AML1-ETO–positive AML patients, but about 40% of patients relapse within 2 years (Zhu et al., 2016). The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.